Perinatal HIV Research Unit

What Perinatal HIV Research Unit does

The Perinatal HIV Research Unit (PHRU) is a South African non-profit clinical research organization founded in 1996 and headquartered at Chris Hani Baragwanath Academic Hospital in Soweto, operating as a research division of the University of the Witwatersrand under the Wits Health Consortium. PHRU conducts multi-disciplinary, GCP-compliant clinical research across HIV prevention (vaccines, PrEP, long-acting agents), HIV treatment optimization (including paediatric, maternal, and adolescent populations), tuberculosis (including drug-resistant TB and the M72 vaccine trial), and COVID-19 vaccine studies, operating five research sites across four South African provinces (Soweto, Aeroton, Matlosana, Botshabelo, Limpopo) and participating in landmark multi-country trials such as PURPOSE 1. Its research portfolio is delivered through NIH-funded networks — HVTN, HPTN, ACTG, and IMPAACT — together with internally branded units (NM Syndicate, Vaccines Research Centre, Social & Bio-behavioural Research Division) and supported by an in-house support services stack: DataLab for data management and AI metadata preparation, Statistics Support for study design and machine learning, GCP/GCLP-certified Pharmacy Services for clinical trial medications, Regulatory Services for SAHPRA and ethics submissions, and the CLEAR Laboratory for PBMC processing, cryopreservation, and biostorage.

PHRU is fully grant-funded, with revenue derived from research grants and clinical trial agreements with the National Institutes of Health (via DAIDS), PEPFAR, the Bill & Melinda Gates Foundation, the South African Medical Research Council, and pharmaceutical sponsors including Gilead Sciences and the Gates Medical Research Institute. The organization does not sell commercial products and operates a community-partnered go-to-market model: four Community Advisory Boards (including an Adolescent CAB / Youth Talk), 26 partnered Soweto TB clinics, and direct community outreach in high-burden townships drive trial recruitment, while ~100 peer-reviewed publications annually provide scientific credibility and inform WHO and FDA recommendations. Notable milestones include the 1996-1997 court case compelling South African government provision of nevirapine (in which PHRU was a plaintiff), the 2001 launch of the first HIV vaccine trial in South Africa, the 2020 Sisonke study vaccinating nearly 500,000 healthcare workers against COVID-19, and the 2025 PURPOSE 1 trial demonstrating 100% efficacy of lenacapavir for HIV prevention among cisgender women.

Leadership combines internationally credentialed researchers — including Executive Director Prof Neil Martinson (Johns Hopkins MPH), Deputy Executive Director Dr Avy Violari (IMPAACT site leader), Non-Executive Director and co-founder Prof Glenda Gray (NRF A-rated scientist, former SAMRC President and CEO), and Lead Biostatistician Prof Kennedy Otwombe (140+ publications) — with site-level directors across each province. Customer-facing outputs are delivered to study participants (HIV-positive pregnant women, adolescents and young women, MSM, TB patients and contacts, healthcare workers) and to global health sponsors; PHRU functions as a contract research organization embedded within an academic institution, with operational scale of 101-250 employees distributed across the five sites.

Name

Perinatal HIV Research Unit

Legal name

Perinatal HIV Research Unit

Website

https://phru.co.za

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

PHRU is a South African non-profit clinical research unit affiliated with the University of the Witwatersrand, conducting GCP-compliant HIV, TB, and COVID-19 vaccine and treatment trials across five sites for global health funders including NIH, PEPFAR, and the Gates Foundation.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Health Care and Social Assistance (62)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN), HIV/AIDS Medicine (HLAKAGAB), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL)

Keywords

• Clinical research services
• HIV vaccine trials
• TB clinical research
• Clinical trial support
• Infectious disease research

Headquarters

HQ city

Soweto

HQ country

South Africa

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Grant Funding: PHRU is fully grant-funded. Major funders include NIH, PEPFAR, Gates Foundation, SAMRC, and pharmaceutical company partnerships for clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

PHRU conducts multi-disciplinary clinical research in HIV, TB, COVID-19, and related infectious diseases through five dedicated research sites across South Africa. The unit operates through NIH-funded research networks (HVTN, HPTN, ACTG, IMPAACT) and investigator-initiated studies, supported by in-house DataLab, Statistics, Pharmacy, Regulatory, and CLEAR Laboratory services. PHRU also provides clinical care, prevention services, and community engagement for study participants in high-burden South African communities.

Product overview

The Perinatal HIV Research Unit (PHRU) is a research institution offering a comprehensive portfolio of clinical research services rather than a traditional product company. The organization operates through multiple research networks (NM Syndicate, HVTN, HPTN, ACTG, IMPAACT) and a Vaccines Research Centre, all supported by core service divisions: DataLab for data management and API integrations, Statistics Support for study design and machine learning, Pharmacy Services for clinical trial medications, Regulatory Services for compliance, and the CLEAR Laboratory for specimen processing. The PHRU also conducts Social & Bio-behavioural research. This structure integrates clinical trials infrastructure with specialized support services to enable multi-site research across HIV, TB, COVID-19, and other infectious diseases throughout South Africa.

Differentiator

Problem solved

Functional benefit

Brands

• CLEAR Laboratory: Clinical Laboratory for Experimental and Analytical Research - GCP-compliant lab offering PBMC processing, cryopreservation, LDMS tracking, IQA proficiency, and secure biostorage.
• DataLab
• Zazi HIV Counselling and Testing Clinic
• Youth Talk (ACAB)

Products and services

• HIV Vaccines Trial Network (HVTN) NIH-funded clinical research site based in Soweto conducting HIV and COVID-19 vaccine trials, advancing global trials and capacity-building to serve high- and low-risk populations across sub-Saharan Africa.
• HIV Prevention Trials Network (HPTN)

Quantifiable outcome

• 100 publications in 2023 influencing policy changes
• +4 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration14 records

AI capability7 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• University of the WitwatersrandcoreStrategic or Co-development PartnerPHRU is a Research Unit of the University of the Witwatersrand and pivotal division of Wits Health Consortium. Research sites affiliated to Wits University with investigators contributing to university research agenda.
• International AIDS Vaccine Initiative (IAVI)coreStrategic or Co-development PartnerIn 2001, PHRU established HIV Vaccine Clinical Trials Unit with funding from IAVI and South African AIDS Vaccine Initiative (SAAVI). Subcontract with Division of AIDS for HIV Vaccines Network clinical trial site.
• HIV Vaccines Trial Network (HVTN)coreStrategic or Co-development PartnerNIH-funded clinical trial network for HIV vaccines. PHRU is critical HVTN site conducting Phase I/IIa and Phase IIb/III efficacy trials. Only site that concurrently enrolled high numbers into three Phase IIb-III trials.
• HIV Prevention Trials Network (HPTN)coreStrategic or Co-development PartnerNIH-funded network focused on HIV prevention. PHRU HPTN CRS in Soweto renowned for enrolling 1,000+ participants in prevention efficacy studies targeting AGYW and MSM populations.
• AIDS Clinical Trial Group (ACTG)coreStrategic or Co-development PartnerPHRU ACTG CRS operational since 2004. Research contributed to WHO recommendations and FDA approvals of antiretroviral doses. Part of PHRU-Setshaba CTU.
• International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT)coreStrategic or Co-development PartnerLed by Dr Avy Violari since inception. One of oldest pediatric clinical trials sites in Africa (since 1996). Focus on optimizing HIV treatment in infants, children, adolescents and pregnant women.
• Johns Hopkins UniversitymajorStrategic or Co-development PartnerExtensive research collaborations including studies on elite controllers of HIV and TB resistance. Prof Martinson completed MPH at Johns Hopkins. Multiple joint publications and research initiatives.
• National Institute for Communicable Diseases (NICD)majorStrategic or Co-development PartnerCollaborator on immune control of HIV research ('elite controllers') and TB infection resistance studies alongside Johns Hopkins University.
• Chris Hani Baragwanath Academic HospitalcoreStrategic or Co-development PartnerTertiary-level teaching hospital (3000 beds) hosting PHRU headquarters and Soweto research site. Provides access to patients with HIV, TB co-infection and malignancies.
• Gilead SciencescoreStrategic or Co-development PartnerSponsor of PURPOSE 1 study evaluating lenacapavir for HIV prevention. Study demonstrated 100% efficacy in cisgender women across South Africa and Uganda sites.
• Gates Medical Research InstitutemajorStrategic or Co-development PartnerSponsor of M72 vaccine trial for TB prevention. Both Matlosana and Soweto sites following up patients in this late-stage vaccine trial.

Scale indicators7 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• HIV Vaccines Trials Network (HVTN): HVTN is the NIH-funded global network coordinating HIV vaccine trials of which PHRU is a member site. It is comparable as the overarching research consortium governing the trials PHRU executes, providing peer benchmarks in network governance and protocol allocation.
• International AIDS Vaccine Initiative (IAVI): IAVI is a global product-development organisation that funded PHRU's HIV Vaccine Clinical Trials Unit in 2001 and continues to co-sponsor protocols. It is comparable as a partner/peer organisation shaping the HIV vaccine pipeline PHRU serves.
• HIV Prevention Trials Network (HPTN): HPTN is the NIH-funded prevention-trials network running the prevention studies (including those in AGYW and MSM populations) that PHRU participates in. It is a structural peer in the global prevention-trial ecosystem.

Regional players

• Centre for Infectious Disease Research in Zambia (CIDRZ): CIDRZ is a Lusaka-based research organisation running PEPFAR/NIH-funded HIV and TB trials in Zambia. It is comparable as a regional African peer performing the same grant-funded clinical-research mission under similar public-sector constraints.

Direct peers

• Desmond Tutu HIV Foundation: Based at the University of Cape Town, the Desmond Tutu HIV Foundation conducts HIV prevention and vaccine trials with a community-based model. It competes with PHRU for adolescent and key-population trial enrolments across South African sites.
• Africa Health Research Institute (AHRI): AHRI is a KwaZulu-Natal-based research institute running HIV/TB clinical trials, population cohorts, and immunology studies. It is a fellow NIH-network-affiliated site and competes with PHRU for HPTN, HPTU, and ACTG protocols.
• The Aurum Institute: Aurum is a large South African health-research NGO specialising in TB, HIV, and vaccine trials with multiple clinical sites. Like PHRU, it is grant-funded (NIH/PEPFAR/Gates), runs GCP-compliant laboratories, and competes for HPTN/HVTN protocols.
• Centre for the AIDS Programme of Research in South Africa (CAPRISA): CAPRISA is a UNAIDS-collaborating centre in Durban running HIV prevention and treatment trials, TB research, and vaccine studies. It directly competes with PHRU for NIH network site selection and sponsor-led protocols in South Africa.
• Wits Reproductive Health and HIV Institute (Wits RHI): Wits RHI is a sister institute at the University of the Witwatersrand running large-scale HIV prevention, PrEP, and adolescent trials. It shares institutional affiliation and overlapping investigator networks with PHRU and competes for the same grant-funded research mandates.

Others

• South African Medical Research Council (SAMRC): SAMRC is PHRU's major national funder (and was formerly led by co-founder Prof Glenda Gray). It is comparable as the broader public-sector research ecosystem within which PHRU operates, including shared grant programmes and overlapping investigators.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/perinatal-hiv-research-unit

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perinatal HIV Research Unit